The amount of development fees.

No definition available.

Name:	plrz_DevelopmentFees
Namespace Prefix:	plrz_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Funding received bearing interest rate.

+ References

No definition available.

+ Details

Name:	plrz_FundingReceivedBearingInterestRate
Namespace Prefix:	plrz_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the percentage of royalties payable.

+ References

No definition available.

+ Details

Name:	plrz_RoyaltiesPayablePercentage
Namespace Prefix:	plrz_
Data Type:	dtr:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Average rate paid on interest-bearing liabilities.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name Regulation S-K (SK)
-Number 229
-Section 1402
-Paragraph b
-Subparagraph (4)
-Publisher SEC

+ Details

Name:	srt_InterestBearingLiabilitiesAverageRatePaid
Namespace Prefix:	srt_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of interest expense on interest-bearing liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name Regulation S-K (SK)
-Number 229
-Section 1402
-Paragraph a
-Publisher SEC

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Name Regulation S-K (SK)
-Number 229
-Section 1402
-Paragraph b
-Subparagraph (1)
-Publisher SEC

+ Details

Name:	us-gaap_InterestExpenseInterestBearingLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitmentsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of cash outflow for fees classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (g)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_PaymentsForFees
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Research and development expense during the period related to the costs of developing and achieving technological feasibility of a computer software product to be sold, leased, or otherwise marketed.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=plrz_PreclinicalSafetyTestsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=plrz_Phase1ClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=plrz_Phase2aClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=plrz_Phase2bClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=plrz_Phase3ClinicalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=plrz_USFoodAndDrugAdministrationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=plrz_EURegulatoryBodyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=plrz_Phase2ClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=plrz_PhaseIIIClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=plrz_IsraeliInnovationAuthorityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=plrz_NurExoneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingent Liabilities (Details) - USD ($) $ in Thousands			12 Months Ended
	Jul. 18, 2022	May 30, 2022	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Commitments and Contingent Liabilities [Line Items]
Royalties payable percentage		3.25%
SOFR interest rate			12 months
Research and Development Expense, Software (Excluding Acquired in Process Cost)	$ 220
Development fees			$ 0	$ 0	$ 0
Preclinical Safety Tests [Member]
Commitments and Contingent Liabilities [Line Items]
Development fees		$ 80
Phase 1 Clinical Trial [Member]
Commitments and Contingent Liabilities [Line Items]
Development fees		120
Phase 2a Clinical Trial [Member]
Commitments and Contingent Liabilities [Line Items]
Development fees		150
Phase 2b Clinical Trial [Member]
Commitments and Contingent Liabilities [Line Items]
Development fees		200
Phase 3 Clinicals [Member]
Commitments and Contingent Liabilities [Line Items]
Development fees		500
U.S. Food and Drug Administration [Member]
Commitments and Contingent Liabilities [Line Items]
Development fees		750
Development fees	1,125
EU Regulatory Body [Member]
Commitments and Contingent Liabilities [Line Items]
Development fees		$ 750
Development fees	1,125
Phase 2 Clinical Trial [Member]
Commitments and Contingent Liabilities [Line Items]
Development fees	500
Phase III Clinical Trial [Member]
Commitments and Contingent Liabilities [Line Items]
Development fees	$ 600
Israeli Innovation Authority [Member]
Commitments and Contingent Liabilities [Line Items]
Funding received, percentage			100.00%
Funding received			$ 772
Minimum [Member] \| NurExone [Member]
Commitments and Contingent Liabilities [Line Items]
Royalties payable percentage	2.25%
Minimum [Member] \| Israeli Innovation Authority [Member]
Commitments and Contingent Liabilities [Line Items]
Royalties payable percentage			3.00%
Maximum [Member] \| NurExone [Member]
Commitments and Contingent Liabilities [Line Items]
Royalties payable percentage	0.25%
Maximum [Member] \| Israeli Innovation Authority [Member]
Commitments and Contingent Liabilities [Line Items]
Royalties payable percentage			4.50%